Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab

被引：6

作者：

Dallari, Simone ^{[1
]}

Franciotta, Diego ^{[2
]}

Carluccio, Silvia ^{[1
]}

Signorini, Lucia ^{[1
]}

Gastaldi, Matteo ^{[2
]}

Colombo, Elena ^{[2
]}

Bergamaschi, Roberto ^{[2
]}

Elia, Francesca ^{[1
]}

Villani, Sonia ^{[1
]}

Ferrante, Pasquale ^{[1
,3
]}

Delbue, Serena ^{[1
]}

机构：

[1] Univ Milan, Dept Biomed Surg & Dent Sci, I-20133 Milan, Italy

[2] Natl Neurol Inst C Mondino, Dept Gen Neurol, Pavia, Italy

[3] Hlth Sci Fdn, Fdn Ettore Sansavini, Lugo, Italy

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2015年 / 287卷

关键词：

Multiple sclerosis; Natalizumab; Monocytes; ANTIBODY NATALIZUMAB; CELLS; MECHANISMS; BIOMARKER; RISK;

D O I：

10.1016/j.jneuroim.2015.08.010

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Natalizumab is a humanized monoclonal antibody against the alpha 4 subunit of VLA-4 integrin that is used to treat conditions such as multiple sclerosis (MS). Although its effects on lymphocytes have been widely described, little is known about its effects on monocytes. Here we described the effects of natalizumab treatment on peripheral blood monocytes from a small cohort of MS patients in terms of relative frequencies and surface integrin (CD49d and CD18) expression. We showed that natalizumab treatment altered the surface integrin expression on monocyte subsets in the peripheral compartment, suggesting a role for them as mediators of natalizumab effects. (C) 2015 Elsevier B.V. All rights reserved.

引用

页码：76 / 79

页数：4

共 21 条

[1] From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines
Banchereau, Jacques
Pascual, Virginia
O'Garra, Anne
[J]. NATURE IMMUNOLOGY, 2012, 13 (10) : 925 - 931
[2] Natalizumab Exerts Direct Signaling Capacity and Supports a Pro-Inflammatory Phenotype in Some Patients with Multiple Sclerosis
Benkert, Thomas F.
Dietz, Lena
Hartmann, Elena M.
Leich, Ellen
Rosenwald, Andreas
Serfling, Edgar
Buttmann, Mathias
Berberich-Siebelt, Friederike
[J]. PLOS ONE, 2012, 7 (12):
[3] Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab
Bonig, Halvard
Wundes, Annette
Chang, Kai-Hsin
Lucas, Sylvia
Papayannopoulou, Thalia
[J]. BLOOD, 2008, 111 (07) : 3439 - 3441
[4] JC Virus Reactivation during Prolonged Natalizumab Monotherapy for Multiple Sclerosis
Chalkias, Spyridon
Dang, Xin
Bord, Evelyn
Stein, Marion C.
Kinkel, R. Philip
Sloane, Jacob A.
Donnelly, Maureen
Ionete, Carolina
Houtchens, Maria K.
Buckle, Guy J.
Batson, Stephanie
Koralnik, Igor J.
[J]. ANNALS OF NEUROLOGY, 2014, 75 (06) : 925 - 934
[5] Multiple sclerosis
Compston, Alastair
Coles, Alasdair
[J]. LANCET, 2008, 372 (9648) : 1502 - 1517
[6] CD49d expression as a promising biomarker to monitor natalizumab efficacy
Defer, Gilles
Mariotte, Delphine
Derache, Nathalie
Toutirais, Olivier
Legros, Helene
Cauquelin, Brigitte
Le Mauff, Brigitte
[J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 314 (1-2) : 138 - 142
[7] Fougerolles A.R. De, 2002, IMMUNOL REV, P208
[8] Jilek S., 2013, MULT SCLER J
[9] Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis
Krumbholz, M.
Meinl, I.
Kuempfel, T.
Hohlfeld, R.
Meinl, E.
[J]. NEUROLOGY, 2008, 71 (17) : 1350 - 1354
[10] Leger Olivier J. P., 1997, Human Antibodies, V8, P3

← 1 2 3 →